Totect

prophylaxis of cardiomyopathy, Drug Extravasation, Metastatic Breast Cancer + 2 more
Treatment
4 FDA approvals
2 Active Studies for Totect

What is Totect

DexrazoxaneThe Generic name of this drug
Treatment SummaryDexrazoxane is a medication used to protect the heart from the harmful effects of another medication called anthracycline. It works by preventing the formation of a toxic compound when anthracycline and iron are combined. The FDA has approved it for use in preventing or reducing the severity of anthracycline-induced cardiomyopathy.
Zinecardis the brand name
Totect Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zinecard
Dexrazoxane
1995
21

Approved as Treatment by the FDA

Dexrazoxane, also known as Zinecard, is approved by the FDA for 4 uses including Metastatic Breast Cancer and doxorubicin .
Metastatic Breast Cancer
doxorubicin
prophylaxis of cardiomyopathy
Metastatic Breast Cancer

Effectiveness

How Totect Affects PatientsDexrazoxane is a drug used to help reduce the risk of heart damage caused by the chemotherapy drug doxorubicin, especially in women with breast cancer. The exact way that doxorubicin causes heart damage is not known, but it is believed to be related to a variety of factors such as changes in the heart muscle, calcium overload, and damage from free radicals. The heart cells are particularly vulnerable to this damage as they don’t have enough enzymes to protect them. Dexrazoxane helps to protect the heart from this damage.
How Totect works in the bodyWe don't know exactly how dexrazoxane works, but it likely works by preventing damage caused by iron-based free radicals. Dexrazoxane also is thought to inhibit a certain enzyme that helps to protect the heart from damage.

When to interrupt dosage

The quantity of Totect is contingent upon the identified illness, such as prophylaxis of cardiomyopathy, doxorubicin and Drug Extravasation. The amount also fluctuates in accordance with the technique of delivery featured in the table underneath.
Condition
Dosage
Administration
prophylaxis of cardiomyopathy
, 250.0 mg, 500.0 mg, 20.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 10.0 mg/mL
, Kit, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Kit - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution
Drug Extravasation
, 250.0 mg, 500.0 mg, 20.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 10.0 mg/mL
, Kit, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Kit - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution
doxorubicin
, 250.0 mg, 500.0 mg, 20.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 10.0 mg/mL
, Kit, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Kit - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution
anthracycline-based chemotherapy
, 250.0 mg, 500.0 mg, 20.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 10.0 mg/mL
, Kit, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Kit - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution
Metastatic Breast Cancer
, 250.0 mg, 500.0 mg, 20.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 10.0 mg/mL
, Kit, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Kit - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Warnings

Totect has two contra-indications. It should not be taken when one is suffering from any of the conditions provided in the subsequent table.Totect Contraindications
Condition
Risk Level
Notes
Pharmacotherapy
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Totect.
Common Totect Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Acteoside.
Totect Toxicity & Overdose RiskThe lowest toxic dose for mice when administered intraperitoneally is 500 mg/kg and for dogs when administered intravenously is 2 gm/kg.

Totect Novel Uses: Which Conditions Have a Clinical Trial Featuring Totect?

73 active studies are underway to analyze the efficacy of Totect in the prevention of cardiomyopathy and in the treatment of anthracycline-based chemotherapy and doxorubicin.
Condition
Clinical Trials
Trial Phases
anthracycline-based chemotherapy
0 Actively Recruiting
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Drug Extravasation
1 Actively Recruiting
Not Applicable
prophylaxis of cardiomyopathy
0 Actively Recruiting
doxorubicin
0 Actively Recruiting

Patient Q&A Section about totect

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When to initiate dexrazoxane?

"Product must be diluted with 50 mL of 0.167 M sodium lactate injection solution prior to administration. Initiate infusion as soon as possible, and within the first 6 hours of extravasation. Start day 2 and 3 treatments at the same hour as the first day, give or take 3 hours."

Answered by AI

How do you give dexrazoxane?

"Dexrazoxane comes in the form of a powder which is to be mixed with liquid and injected intravenously by a healthcare professional in a hospital. It is given over the course of 15 minutes just before each dose of doxorubicin in order to prevent any heart damage that might be caused by the latter medication."

Answered by AI

Clinical Trials for Totect

Image of University of Miami/Sylvester at Plantation in Plantation, United States.

Combination Therapy for Breast Cancer

18 - No maximum age
All Sexes
Plantation, FL
This is an open-label, phase I/II double arm study of the SV-BR-1-GM regimen in combination with retifanlimab in patients with metastatic or locally recurrent breast cancer who have failed standard therapy. Patients will receive the SV-BR-1-GM regimen with combination immunotherapy. There will be an initial evaluation of the combination of the SV-BR-1-GM regimen with retifanlimab every 3 weeks. If this is found to be safe and well tolerated in a cohort of at least 12 patients (dose-limiting toxicities (DLTs) in less than 30% of the patients evaluated), then an expansion cohort of up to 24 patients will be treated with that combination. These will be randomized to two regimens differing in the timing of checkpoint inhibitor administration.
Phase 1 & 2
Waitlist Available
Quick Reply
University of Miami/Sylvester at Plantation (+13 Sites)George E Peoples, MD, FACSBriaCell Therapeutics Corporation
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security